본문 바로가기
KERD
논문KCI 등재

망막분지정맥폐쇄에 의한 황반부종에서 유리체강내 베바시주맙 주입술의 장기효과

Long-Term Effects of Intravitreal Bevacizumab Injection for Macular Edema Secondary to Branch Retinal Vein Occlusion

김현웅|윤일한|송인제
대한안과학회 (The Korean Ophthalmological Society)|2012.02|대한안과학회지 (Journal of The Korean Ophthalmological Society)|제53권 제2호|pp. 283-290

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

Macular edemaBevacizumabIntravitreal injectionBranch retinal vein occlusion
주제분류안과학

초록

목적: 망막분지정맥폐쇄에 의한 황반부종에서 유리체강내 베바시주맙 주입의 장기효과를 알아보았다. 대상과 방법: 시력 20/40 (logMAR 0.3) 이하이며 황반두께가 250 μm 이상으로 유리체강내 베바시주맙 주입술을 시행 후 12개월 이상경과관찰 하였던 47명 47안을 대상으로, 1회 주입 후 황반부종이 호전된 군, 지속된 군, 호전 후 재발한 군으로 나누어 12개월째 치료전, 후 시력 및 황반두께를 비교하였다. 결과: 술 후 시력은 1회 주입 후 황반부종이 호전된 군 0.50 (± 0.30), 황반부종이 재발한 군에서 0.76 (± 0.51) 황반부종이 지속된군에서 0.55 (± 0.35) logMAR unit으로 3군 모두 술 전 (0.96 ± 0.32, 1.13 ± 0.42, 0.85 ± 0.24)에 비해 유의하게 호전되었으며, 중심황반두께 또한 술 전 510.84 (± 171.07), 538.5 (± 216.87), 522.6 (± 101.82) μm에서 술 후 211.58 (± 42.74), 232 (± 132.68), 270.6(± 85.27) μm로 호전되었다. 결론: 망막분지정맥폐쇄 환자에서 베바시주맙 유리체강내 주입술은 최대교정시력 및 황반부종의 호전을 가져왔다.

Abstract

Purpose: To report the long term effects of intravitreal bevacizumab injection (IVAI) for the treatment of macular edema due to branch retinal vein occlusion (BRVO). Methods: In this retrospective study, 47 consecutive patients (47 eyes) whose visual acuity under 20/40 and macular thickness over 250 μm from BRVO received IVAI (1.25 mg). All patients were observed over 12 months. The patients were classified into three groups: one, resolved macular edema after first injection, second, persistant, third, recurrant. At 12 months after injection, best corrected visual acuity (BCVA) and central macular thickness (CMT) were compared with one another. Results: Comparing with baseline BCVA (0.96 ± 0.32, 1.13 ± 0.42, 0.85 ± 0.24 log MAR unit), the mean at 12 months was significantly increased (0.50 ± 0.30, 0.76 ± 0.51, 0.55 ± 0.35) in each group. The mean CMT at baseline was 510.84 (±171.07), 538.5 (± 216.87), 522.6 (± 101.82) μm decreased to 211.58 (± 42.74), 232 (± 132.68), 270.6 (± 85.27). Conclusions: IVAI was a result of significant decrease of CMT with improvement of BCVA in patients with BRVO after a follow-up of 12 months.

참고문헌 (51)

  1. Scott IU., "Vitreoretinal surgery for complications of branch retinal vein occlusion", Curr Opin Ophthalmol, 13, pp.161~166 (2002)
  2. Finkelstein D, "Branch and central vein occlusions. Focal Points 1987: clinical modules for ophthalmologists", Am Acad Ophthalmol, 5, pp.1~11 (1987)
  3. Rehak J, "Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities", Curr Eye Res, 33, pp.111~131 (2008)
  4. Branch Vein Occlusion Study Group, "Argon laser photocoagulation for macular edema in branch vein occlusion", Am J Ophthalmol, 98, pp.271~282 (1984)
  5. Weiter JJ, "The influence of photoreceptor-RPE complex on the inner retina. An explanation for the beneficial effects of photocoagulation", Ophthalmology, 87, pp.1133~1139 (1980)
  6. Jonas JB, "Intraocular pressure after intravitreal injection of triamcinolone acetonide", Br J Ophthalmol, 87, pp.24~27 (2003)
  7. Jonas JB, "Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide", Eye (Lond), 19, pp.65~71 (2005)
  8. Avitabile T, "Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema", Am J Ophthalmol, 140, pp.695~702 (2005)
  9. Cekic O, "Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion", Retina, 25, pp.851~855 (2005)
  10. Ozkiris A, "Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion", Eye (Lond), 20, pp.13~17 (2006)
  11. Ferrara N, "Vascular endothelial growth factor: basic science and clinical progress", Endocr Rev, 25, pp.581~611 (2004)
  12. Adamis AP, "The role of vascular endothelial growth factor in ocular health and disease", Retina, 25, pp.111~118 (2005)
  13. Noma H, "Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion", Graefes Arch Clin Exp Ophthalmol, 244, pp.309~315 (2006)
  14. Pe’er J, "Vascular endothelial growth factor upregulation in human central retinal vein occlusion", Ophthalmology, 105, pp.412~416 (1998)
  15. Rabena MD, "Intravitreal bevacizumab(Avastin) in the treatment of macular edema secondaryto branch retinal vein occlusion", Retina, 27, pp.419~425 (2007)
  16. Spandau U, "Intravitreal bevacizumab for branch retinal vein occlusion", Acta Ophthalmol Scand, 85, pp.118~119 (2007)
  17. Costa RA, "Intravitreal bevacizumab(avastin) for central and hemicentral retinal vein occlusions:IBeVO study", Retina, 27, pp.141~149 (2007)
  18. Wu L, "Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up", Retina, 28, pp.212~219 (2008)
  19. Kriechbaum K, "Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study", Br J Ophthalmol, 92, pp.518~522 (2008)
  20. Kreutzer TC, "Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion", Br J Ophthalmol, 92, pp.351~355 (2008)
  21. Jaissle GB, "One- year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion", Graefes Arch Clin Exp Ophthalmol, 247, pp.27~33 (2009)
  22. Prager F, "Intravitreal bevacizumab(Avastin) for macular oedema secondary to retinal vein occlusion:12-month results of a prospective clinical trial", Br J Ophthalmol, 93, pp.452~456 (2009)
  23. Kondo M, "Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis", Retina, 29, pp.1242~1248 (2009)
  24. Chung EJ, "Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion", Graefes Archive For Clinical And Experimental Ophthalmology, 246, pp.1241~1247 (2008)
  25. Klein R, "The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study", Trans Am Ophthalmol Soc, 98, pp.133~141 (2000)
  26. Mitchell P, "Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study", Arch Ophthalmol, 114, pp.1243~1247 (1996)
  27. David R, "Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure", Ophthalmologica, 197, pp.69~74 (1988)
  28. Gutman FA, "The natural course of temporal retinal branch vein occlusion", Trans Am Acad Ophthalmol Otolaryngol, 78, pp.178~192 (1974)
  29. Hayreh SS, "Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion", Ophthalmology, 90, pp.488~506 (1983)
  30. Magargal LE, "Temporal branch retinal vein obstruction: a review", Ophthalmic Surg, 17, pp.240~246 (1986)
  31. Michels RG, "Natural course of temporal retinal branch occlusion", Trans Am Acad Ophthalmol Otolaryngol, 78, pp.178~192 (1974)
  32. Stefánsson E, "The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology", Acta Ophthalmol Scand, 79, pp.435~440 (2001)
  33. Kalogeropoulos C, "Morphology of early retinal lesions after experimental venous occlusion", Klin Monbl Augenheilkd, 208, pp.375~376 (1996)
  34. Larsson J, "The 30-Hz flicker cone ERG for monitoring the early course of central retinal vein occlusion", Acta Ophthalmol Scand, 78, pp.187~190 (2000)
  35. Rabena MD, "Intravitreal bevacizumab(Avastin) in the treatment of macular edema secondaryto branch retinal vein occlusion", Retina, 27, pp.419~425 (2007)
  36. Matsumoto Y, "Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease", Retina, 27, pp.426~431 (2007)
  37. Campochiaro PA, "Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator", Mol Ther, 16, pp.791~799 (2008)
  38. Jaissle GB, "Bevacizumab for treatment of macular edema secondary to retinal vein occlusion", Ophthalmologe, 103, pp.471~475 (2006)
  39. Ahmadieh H, "Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab", Int Ophthalmol, 26, pp.191~193 (2005)
  40. Yazdani S, "Intravitreal bevacizumab(Avastin) injection for neovascular glaucoma", J Glaucoma, 16, pp.437~439 (2007)
  41. Kahook MY, "Intravitreal bevacizumab in a patient with neovascular glaucoma", Ophthalmic Surg Lasers Imaging, 37, pp.144~146 (2006)
  42. Campochiaro PA, "Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study", Ophthalmology, 117, pp.1102~1112 (2010)
  43. 이한기, "망막분지정맥폐쇄의 황반부종에 대한 유리체강내 베바시주맙 주입술의 효과", 대한안과학회지, 50(12), pp.1800~1808 (2009), 대한안과학회
  44. Wetzig PC, "The treatment of acute branch vein occlusion by photocoagulation", Am J Ophthalmol, 87, pp.65~73 (1979)
  45. Krohne TU, "Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans", Am J Ophthalmol, 146, pp.508~512 (2008)
  46. Stewart MW, "Predicted biologic activity of intravitreal bevacizumab", Retina, 27, pp.1196~1200 (2007)
  47. Ach T, "Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion", Graefes Arch Clin Exp Ophthalmol, 248, pp.155~159 (2010)
  48. Lang GE, "Results of laser coagulation of retinal branch vein occlusion", Klin Monatsbl Augenheilkd, 203, pp.180~188 (1993)
  49. Shilling JS, "Retinal branch vein occlusion: a study of argon laser photocoagulation in the treatment of macular oedema", Br J Ophthalmol, 68, pp.196~198 (1984)
  50. Duff IF, "Anticoagulant therapy in occlusive vascular disease of retina", AMA Arch Ophthalmol, 46, pp.601~617 (1951)
  51. Shroff D, "Natural history of macular status in recent-onset branch retinal vein occlusion: an optical coherence tomography study", Int Ophthalmol, 28, pp.261~268 (2008)

관련 논문AI추천

망막분지정맥폐쇄에서 황반부종 치료로 유리체강내 베바시주맙 주입술의 장기 효과박정민, 안성민, 이수정대한안과학회 · 대한안과학회지2014 · 제55권 제3호망막분지정맥폐쇄에 동반된 황반부종의 자연경과와 유리체강내 베바시주맙 주입술 결과의 비교사공민, 오현주, 장우혁대한안과학회 · 대한안과학회지2013 · 제54권 제7호망막분지정맥폐쇄에 동반된 황반부종에서 베바시주맙치료 결과유웅선, 정인영, 조용운, 최영제, 최유진대한안과학회 · 대한안과학회지2021 · 제62권 제9호망막분지정맥폐쇄에 동반된 황반부종에서 유리체강내 베바시주맙주입술의 반복성에 관련된 인자강경태, 김광수, 김유철대한안과학회 · 대한안과학회지2015 · 제56권 제10호분지망막정맥폐쇄에서 폐쇄부위에 따른 유리체강 내 베바시주맙주입술의 치료효과김주연, 최경섭대한안과학회 · 대한안과학회지2017 · 제58권 제10호망막분지정맥폐쇄에서 황반부종 형태에 따른 유리체강내 베바시주맙 주입술 효과와 주입횟수 비교이동원, 장윤수대한안과학회 · 대한안과학회지2012 · 제53권 제8호

이 간행물의 다른 논문 (24건)

변형된 방추형결막절제술 및 가쪽눈꺼풀판띠고정술에 의한 퇴행성 눈꺼풀겉말림의 교정김상덕, 고상준pp. 187-192건성안 환자에서 페놀레드 검사의 임상적 유용성위성욱, 전연숙, 문남주, 김재찬pp. 193-199양막이식술을 이용한 군날개 제거술에서 마이토마이신 C의 효과박대진, 이진기, 김정규, 배성근pp. 200-207유수정체용 전방각지지렌즈 삽입 후 각막내피세포의 장기 변화양재니, 이진기pp. 208-214자가윤부결막이식술을 이용한 군날개 제거술에서 결막하 섬유혈관 조직의 광범위절제술의 효과배성근, 박대진, 이진기pp. 215-222
원문 보기